




PHARMACEUTICAL 2018

Corvus Pharmaceuticals Inc.
Rank 97 of 342





PHARMACEUTICAL 2018

Corvus Pharmaceuticals Inc.
Rank 97 of 342

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 48% points.

The company's Economic Capital Ratio, given in the ranking table, is 172%, being 127% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	91,234
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,969
Liabilities, Non-Current	971
Other Assets	869
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	861
Other Revenues	0
Property and Equipment	2,672
Research and Development	46,305
Selling, General and Administrative Expense	10,219

Output Variable	Value in 1000 USD
Assets	94,775
Liabilities	9,940
Expenses	56,524
Revenues	0
Stockholders Equity	84,835
Net Income	-55,663
Comprehensive Net Income	-55,664
Economic Capital Ratio	172%